- Ticagrelor
Drugbox
IUPAC_name = (1S,2S,3R,5S)-3- [7- [(1R,2S)-2-(3,4-Difluorophenyl)cyclopropylamino] -5-(propylthio)-3H- [1,2,3] triazolo [4,5-d] pyrimidin-3-yl] -5-(2-hydroxyethoxy)cyclopentane-1,2-diol
CAS_number = 274693-27-5
CAS_supplemental =
ATC_prefix =
ATC_suffix =
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
C=23 | H=28 | F=2 | N=6 | O=4 | S=1
molecular_weight = 522.567 g/mol
smiles = Fc2ccc(cc2F)C3CC3Nc5nc(SCCC)nc4c5nnn4C1CC(C(O)C1O)OCCO
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration = oralTicagrelor (AZD6140) is a
platelet aggregation inhibitor produced byAstraZeneca . as of|February 2008, a clinical trialclinical trial (PLATO: Platelet inhibition and patient outcomes) is comparing a combination of ticagrelor plusaspirin toclopidogrel plus aspirin for the prevention ofthromboembolism .Method of action
Like clopidogrel and
ticlopidine , ticagrelor blocksADP receptor s of subtype P2Y12. In contrast to the other antiplatelet drugs, it blocks the receptor reversibly. Moreover, does not needhepatic activation, which could reduce the risk ofdrug interactions .References
* cite journal
author = H. Spreitzer
date =February 4 ,2008
title = Neue Wirkstoffe - AZD6140
journal = Österreichische Apothekerzeitung
issue = 3/2008
pages = 135
language = German
* cite journal
author = Owen, RT, Serradell, N, Bolos, J
title = AZD6140
journal = Drugs of the Future
year = 2007
volume = 32
issue = 10
pages = 845-853
Wikimedia Foundation. 2010.